Technological advances and the next 50 years of cardiology  by Flower, Joe et al.
lourn',d of the American College of Cardiology 
~3 2000 by the American College of Cardiology 
published by Elsevier Science Inc. 
Vol. 35, No. 5, Suppl B 
ISSN 0735-1097/00/$20.00 
PII S0735-1097(99)00558-1 
Technological Advances and 
the Next 50 Years of Cardiology 
Joe Flower, M.A, Leonard S. Dreifus, MD,  MACC,*  Alfred A. Boy6, MD,  PhD,  FACC,]" 
William S. Weintraub, MD,  FACC3~ 
Tampa, Florida; Philadelphia, Pennsylvania; ./ltlanta, Georgia 
THINKING ABOUT THE FUTURE 
Think of every belief you have about health care, every 
a~sumption (e.g., "I get sick, I go to the doctor. . .  "). Now, 
turn each one over, pull it inside out, imagine how it could 
bc made false (e.g., "What if I don't wait until I am sick? 
\Vhat if the doctor comes to me? What if the help that 
comes is not a doctor? How could that be? . . .  "). 
This is the future of healthcare. The combination of 
demographic shifts and cost pressures and a flood of new 
technologies--both biological and digital--promise that 
the new century and the coming generation will see the 
creative destruction and rebirth of what we know today as 
health care. 
In no field is this more true than in cardiovascular 
medicine, situated as it is at the nexus of the most advanced 
technologies, the most expensive techniques, the conditions 
most sensitive to changing lifestyles and demographics, and 
the deepest scientific understandings. 
In the coming years, and even during just the next decade, 
cardiovascular medicine will undergo radical changes in 
technique and understanding, even as health care undergoes 
radical changes in structure, payment systems, and informa- 
tion flow. Cardiovascular medicine will never again be what 
11 was. 
Yet we can make no specific predictions; crystal balls do 
n~t work. The future is unknown. Whatever the future of 
cardiovascular medicine is, it will not be exactly the way we 
paint it here. There are too many unknowns and even 
,nknown unknowns. 
So, how can we think about the future at all? We can 
create scenarios, reasonably plausible depictions based on a 
'nixture of current breakthroughs, promising current re- 
search, and thoughtful extrapolations from current research. 
We can offer more detailed pictures of how events might 
ttn(old if current research produces results. Finally, to 
~upport hese future imagcs, we can offer an overview of 
where we are now: today's most promising areas of research 
and their possible future developments. 
I:r,,n the *University of South Florida, Tampa, Rorida; "l-Temple University 
I I'slntal, Philadelphia, Pcnnsylvama; nd :~Emory Unlversit3,, Atlanta, Georgia. 
SCENARIOS 
2009. At 60, you actually feel better than you did at 50, 
because of exercise, plenty of sleep, moderate habits, and the 
fact that you quit smoking at 50. But you have not been to 
the doctor much lately, so when you ask your physician to 
authorize aphysical examination, you get a bit of a surprise. 
You expected more probing, a detailed talk with the doctor, 
and maybe some tests of blood or urine. Instead, the 
technician pricks your finger, takes a single drop of blood 
with a hand-held evice the size of a computer mouse, and 
says, "Thank you. That will be alL" Two minutes later, as 
you are still putting the bandage on your finger, the 
technician pops back into the room, hands you a printed 
slip, and says, "You're going to have to come talk to the 
life-stylist. You have no symptoms yet, but your genome 
says you're heading for heart disease." 
2024. At 75, you still feel better than you did at 50, again 
because of exercise, plenty of sleep, and moderate habits as 
well as breakthroughs in antiglycosylation therapy. The man 
sitting next to you on the rocket plane to Mumbai seems 
quite normal, until the conversation you are having with 
him takes an odd twist, and you swap medical histories. You 
learn that he has a pig heart, and his arteries are swarming 
with "smart dust" that constantly reports on his condition, 
directly over the Internet, to his physician's database. These 
facts strike you as strange, a coincidence worthy of com- 
ment, because you have a pig heart, too. In fact, the man 
tells you, it is not strange at all anymore. 
2049. At 100, you still feel better than you did at 50, still 
because of exercise, plenty of sleep, and moderate habits as 
well as breakthroughs in antiglycosylation therapy, whole- 
sale organ replacement in your eighties, and the nanolabs in 
your blood stream that manufacture pharmaceuticals a
needed and constantly top up your telomerase, the enzyme 
that makes your cells immortal. "With all of this help, your 
cardiovascular system ticks like a grandfarl~er clock, and you 
nev'_':-.~i~,e it a se::,n,I thought. You J w ~:'..'n up on 
retirement. Who could .',fiord it anyway, -" _i~ sc many Baby' 
Boomers hanging on 1": .:t [00? 
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IMAGES OF THE NEAR FUTURE: 1999-2009 
Genomic revolution. It is 2009. During the past 10 years, 
the unraveling of the human genome has turned out to be 
the Rosetta Stone of the human body. The work of the 
Human Genome Project, together with the work of such 
private firms as Celera and Human Genome Sciences--to 
parse the genome at the turn of the century--was a true 
turning point in medical history and in the history of 
cardiovascular medicine. 
Every diseasc in fact, every state of the human body--is 
the result of some genes expressing proteins and some genes 
suppressing other genes or modifying proteins expressed by 
other genes. The picture will never be simple, but eventually 
our understanding of the human genome will tell us what 
actually is happening in our cells. In this way, genomics (the 
study of the genome), proteomics (the study of the flail 
complement of human proteins), bioinformatics (the tech- 
niques of gathering and processing all of this knowledge), 
and systems biology (the study of how all of these processes 
work as a complex adaptive system) are fundamentally 
different from all medical studies preceding them. Other 
studies dealt with effects; whereas these studies are the first 
to give us a direct look at the actual biochemical pathways of 
human development, health, and disease. 
In cardiovascular medicine, the results of these genomic 
studies have been realized in two main paths: predictive 
diagnostics and pharmaceuticals. 
PREDICTIVE POWER OF GENOMICS. Genomics and bioin- 
formatics have given cardiovascular specialists a powerful 
new tool--the ability to predict heart disease ven decades 
before symptoms appear (1). 
By the end of the decade, inexpensive hand-held biosen- 
sors had been introduced and were capable of detecting a
wide range of diseases within minutes by analyzing adrop of 
blood, urine, saliva, or breath or even by bouncing micro- 
radar off of the skin (2). The core of this hand-held device 
is the "lab on a chip" (a miniature chemical aboratory as 
small as 3 mm square) combined with a micro-array chip 
that fluoresces in patterns that advertise the presence of 
particular proteins or gene expressions and an analysis chip 
that compares the pattern of genes or proteins expressed to 
known patterns associated with particular disease states 
(3,4). Some chips search for tell-tale single-nucleotide 
polymorphisms (SNPs), which are patterns of tiny gene 
mutations that have been shown to be predictive of heart 
disease. Pharmacogenomic chips search for SNPs that tell 
how the patient will respond to particular drugs. 
Pharmaceutical firms, as recently as the early 1990s 
starved for candidate compounds to test, have been wading 
through tens of thousands of possibilities, using the growing 
areas of genomics, proteomics, bioinformatics, and auto- 
mated compound searches. The resulting flood of powerful 
new pharmaceuticals has begun to render many surgeries 
unnecessary: 
• The use of cholesterol-controlling statins steadily in- 
creased throughout he decade as knowledge of their 
benefits pread among generalists, prices fell, and generic 
brands appeared; 
• Angiogenesis drugs, such as vascular endothelial growth 
factor (VEGF), obviated the need for much bypass 
surgery by growing new arteries on damaged hearts; 
• Anti-angiogenesis drugs (e.g., endostatin), locally im- 
planted in arterial plaque, inhibit its growth; 
• Myogenesis drugs rebuild damaged heart muscles; 
• Antiglycosylation therapies prevent he cross-linking that 
weakens aging heart muscle; 
• New vaccines raise high-density lipoprotein (HDL) levels 
to help stave off heart disease; 
• New genomic therapies repair damage after a myocardial 
infarction and prevent he mass apoptosis that commonly 
follows; 
• A nicotine vaccine allows smokers who wish to quit 
smoking to rid themselves of the physical craving for 
cigarettes; and 
• New antibiotics are used prophylactically to prevent 
chlamydia and other infections, which cardiovascular 
specialists continue to investigate as a cause of cardiovas- 
cular disease. 
Nutriceuticals. These new surgical and pharmaceutical 
therapies have combined with the rapid rise in popularity of 
nutficeuticals, or so-called functional foods, that actively 
contribute to heart health. Margarines and cooking oils 
made with plant sterols and stanols, which "taste fat" but 
actually lower low-density lipoprotein (LDL) cholesterol 
and raise HDL cholesterol, have replaced butter, other 
cooking oils, and other fats in many packaged foods and 
fast-food offerings. Major packagers of common foods, from 
breakfast cereals to frozen foods, market "heart-healthy" 
lines high in plant sterols and stanols and flavonoid anti- 
oxidants (5-11). 
Surgery. In the decade since 1999, surgical techniques and 
devices have continued their rapid improvements. Stents 
have proliferated into a wider range of sizes and are capablc 
of working in smaller arteries. New materials have greatly 
reduced the incidence of restenosis. Catheters have likewise 
become smaller and more maneuverable, affording surgeons 
a wider range of insertion points and a plethora of capabil- 
ities, from the now-traditional ngioplasty to the decade-old 
electrical killing of fibrillating cells, laser techniques to 
encourage the growth of new blood vessels, and the direct 
placement of new angiogenesis drugs. 
Tools for performing surgery on beating hearts have 
proliferated from the few available in 1999 to dozens. In 
fact, most heart operations are conducted without stopping 
the heart. 
Minimally invasive surgery and intervention techniques 
are now used for all routine heart surgeries, even intracardiac 
(inside the heart) surgery. Cracking the chest is reserved for 
rare and difficult cases or for full organ replacement. 
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Robotics. Surgical robots, first introduced in the late 
1990s, have become common as well. All major hospitals 
use them for their greater precision and speed, lower cost, 
and shorter ecovery times. Whereas the first robots either 
operated cameras and lights or were direct extensions of the 
surgeon's hands, robots are now more often actually per- 
forming surgery--cutting, clamping, and suturing at the 
surgeon's direction, guided by voice commands ("Robot, 
suture"), by the movements of a mouse on a screen (high- 
light the area, click on "suture"), or by programming based 
on pre-operation three-dimensional images. 
Imaging. Imaging has continued the rapid improvement of
the previous decades. Magnetic resonance (MR) images 
taken via catheter are now commonplace. Since the late 
1990s, image-processing techniques have combined data 
fiom a wide variety of sources (including angiography, 
computerized tomography [CT], MR, electron-beam 
[EBCT], echocardiogram, and MR echocardiogram) to 
produce three-dimensional, scalable images (12,13). Ten 
yc~s later, advances in processing power and software allow 
surgeons not only to see three-dimensional images of the 
patient's actual heart but also to tour the heart in "virtual 
reality" and in real time, even as they operate, without the 
necessity of placing a lens inside the body. 
Replacement hearts. Electromechanical replacement 
hearts have become common. It is no longer unusual to see 
older people at the beach wearing battery packs at their belts 
and taking them off for a dip in the surf (14). The cost 
associated with these replacements is less than half of the 
cost of a human heart transplant (15). Less obvious are the 
thousands of people walking around with swine hearts, 
which are now beginning to be used in situations that 
previously would have called for reparative surgery (16-18). 
Equally important are the thousands of people with replace- 
ment coronary arteries constructed from bovine and swine 
collagen (19). 
Patient data. Connecting heart patients with practitioners 
tbr daily check-ins through software, the Internet, and 
small, easy-to-use home monitors has become standard 
practice, widely praised for keeping patients stable and 
healthy while keeping costs down. For some higher-risk 
patients, daily monitoring is not enough. They conduct 
their daily business while wearing "smart clothing"-- 
undershirts, bras, or belts that monitor basic vital signs, such 
as pulse. The moment hat any dangerous pattern emerges 
(e.g., a racing pulse, fibrillation, or wide variations in heart 
rate), a nurse at the patient's disease management provider 
is alerted through the Internet or the cellular phone system 
and initiates a response (20). 
Electronic medical records built around an industry-wide 
information standard have become the norm. In fact, most 
people carry their own records with them. Some carry the 
information in "smart cards" with embedded ata chips. 
Others carry credit-card-size CD-ROMs that can be read 
by any computer, or a card imprinted with a Web address 
and personal identification umber that gives online access 
to their records (21). 
Standardization of diagnoses and clinical practice. At 
the same time that these new techniques and treatments 
have revolutionized cardiovascular medicine, clinical prac- 
tice has become more standardized across the U.S. and even 
around the globe. The massive efforts of the American 
College of Cardiology (ACC)-National Cardiovascular 
Data Registry TM (NCDR TM) and other organizations in 
collecting, analyzing, and disseminating information have 
resulted in a general set of consensus guidelines. These 
guidelines evolve constantly with new in-the-lab medical 
research results and with new in-the-field information about 
outcomes (what actually happens when real people with real 
heart disease and real complications receive particular ther- 
apies). This widespread reporting system allows the spe- 
cialty as a whole to stay continuously aware of unfolding 
best practices, and this concentrated data study dramatically 
narrows the range of unnecessary variation, thereby leading 
to higher standards of care and, in many cases, lower costs. 
Diagnosis also has become far more standardized. The 
College has led a major drive to identify genomic and 
proteomic patterns that display a wide variety of types of 
heart disease or predict it years in advance. 
THE NEXT GENERATION: 2009-2024 
It is 2024. 
In the face of an older population, the number of cardiac 
surgeries has actually fallen as the Baby Boom generation 
has aged. The maturing genomic revolution has led to an 
array of drugs that together have brought much of heart 
disease under pharmaceutical control. 
Heart exchange is the single most common type of 
open-chest surgery. In fact, except for unusual circum- 
stances, it is the only type. Swine hearts are now common in 
older people. After a furious ethical debate, the use of 
organs from pigs has surged from the few thousand of the 
first decade of the century to hundreds of thousands per 
year, supplanting virtually all types of surgery meant to 
repair a failing heart, including bypass grafting, resection- 
ing, and valve replacements (22). 
The mechanical alternative has improved greatly in a 
generation. Not only has it become far more reliable, but 
also it no longer needs to have its batteries recharged. 
Instead, it is driven, just like a native heart, by the body's 
own metabolism. 
Neo-organs'--replacement organs grown in the labora- 
tory from the patient's own cells--have finally become a 
clinical reality. In a generation of slowly expanding experi- 
ments, researchers have moved from growing thin sheets of 
heart muscle capable of sustaining a heartbeat to growing 
entire hearts, complete with vessels for carrying the blood 
supply, shaped over armatures that then dissolve (23). 
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The first nanomachines have now entered cardiovascular 
medicine, repairing and clearing arteries as well as delivering 
pharmaceuticals to precisely targeted sites (24-28). Nano- 
tech has also produced "smart materials," used for arterial 
walls, connective tissue, and even replacement muscle tissue, 
that mimic natural human tissue in adapting to their site 
and responding to hormonal and nervous ignals (29). 
Nanotechnology has also produced sensing devices the 
size of bacteria, covered with a protein skin that mimics 
human blood cells. Injected into the body, these "smart- 
dust" sensors circulate harmlessly in the bloodstream, re- 
cording body chemistry, hemodynamic flow and pressure, 
and whatever else they had been programmed to look for. 
They report the information to outside monitors by con- 
structing characteristic information signatures easily de- 
tected by the inexpensive monitors in the shape of full- 
length mirrors, scanners, or the next generation of "smart 
clothing" (30). 
Biotechnology has produced harmless cigarettes laced 
with nonaddictive nicotine substitutes, its tars and multiple 
other substances subtly altered to render them harmless 
while still satisfying to the smoker. 
"Just-in-time" knowledge. Over this quarter century, the 
ACC-NCDR TM has evolved into the single most powerful 
and centralized tool for managing and combating heart 
disease. It catalogues outcomes of millions of cases across 
the U.S. and around the world. It steadily turns those 
outcome studies into practice guidelines and disseminates 
them to primary practitioners and specialists alike. 
At the same time, the ACC-NCDR TM has participated in
identifying the genomic and proteomic fingerprints of every 
variety of cardiovascular disease, allowing nearly instant and 
nearly certain diagnosis. 
As the baby boomers age, the demand for cardiovascular 
knowledge and care rapidly increases, and many boomer 
cardiologists retire. Encouraging more medical students to 
enter the specialty is important and useful, but insufficient, 
so the ACC has moved aggressively to use technical means 
to overcome the problem. 
By 2015, the ACC-NCDR TM has built genomic finger- 
prints, more traditional diagnostic riteria, and its practice 
guidelines and scientific notes into diagnostic-assistance 
software that is constantly updated over the Internet. By 
answering a series of questions and entering test results, a 
primary practitioner or nurse can diagnose a patient's heart 
problem as if the most skilled specialist were standing at his 
or her elbow. 
One version of the software watches the patterns of 
information that physicians or nurses enter into a patient's 
electronic record. When patterns emerge that suggest a 
different diagnosis or therapy, the software comes to the fore 
to ask questions and offer "just-in-time" information tai- 
lored to the particular patient and the clinical situation. 
Spreading accurate, useful cardiovascular clinical knowl- 
edge as widely as possible through every technique that 
works has become aprimary goal of the College's NCDR TM 
and the ACC in general. 
Altogether, the field of cardiovascular medicine is more 
important han ever, as rapid advances in organ replace- 
ment, pharmaceuticals, telomerase therapy, and antiglyco- 
sylation therapy have combined to produce extraordinarily 
youthful aging baby boomers. The boomers ee opening up 
to them the possibility of living much longer than an), 
previous generation, and they will pursue any therapy at any 
cost--paid for by them, by their insurance, or by society-- 
that will lengthen their lives. 
OUR CHILDREN AND GRANDCHILDREN: 2024-2049 
It  is 2049. 
Heart replacement surgeries, which peaked about 2024, 
are now almost nonexistent. Today, few hearts, whether 
native human hearts or the old xenotransplants, become 
damaged enough to need surgical repair or replacement. 
The tremendous and continuing exploration of the 
genomic roots of heart disease have brought a continuous 
and rapid improvement in prediction, diagnosis, and phar- 
maceutical therapies. 
By the 2020s, most people were being scanned annually 
(and those at high risk, more often) by technologists armed 
with hand-held genomic scanners. In the early years, the 
information led to recommendations for lifestyle changes, 
such as shifts in diet, exercise patterns, smoking, or other 
consumption habits. 
By the 2030s, however, the hand-held scanners were no 
longer needed. Injectable "smart dust" had advanced to the 
point that it could continually report, and deliver as part of 
the daily routine, genomic shifts and changes in language 
that the consumer could understand. At the same time, the 
recommendations changed from diet and lifestyle to phar- 
maceuticals. 
Pharmaceuticals had become so successful at preventing 
cardiovascular damage--and repairing any damage that did 
occur--that diet and lifestyle changes were no longer 
necessary. People could eat whatever they wanted, smoke, 
and avoid exercise while their cardiovascular systems 
pumped away like antique mechanical Swiss watches--as 
long as they took the pharmaceuticals the mirror prescribed. 
By the 2040s, even the pharmaceuticals were rapidly 
becoming outmoded. Nanotechnology had gone beyond 
"smart dust" to universal bio-assemblers. Floating in the 
bloodstream, these minuscule factories could act on 
genomic information derived on their travels through the 
bloodstream, combined with information and reprogram- 
ming continually and automatically downloaded from the 
Internet as medical science arrived at new understandings. 
The bio-assemblers could put together the needed pharma- 
ceuticals on demand from locally available chemicals in the 
bloodstream. 
As the ACC approaches its centenary celebration in 
2049, it finds itself engaged in a far-reaching and furious 
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debate within its ranks. The question is "Should the ACC 
reconstitute itself in some new shape for its second century?" 
Some radicals even suggest hat the College should be 
abolished, that the specialty of cardiovascular medicine itself 
should go the way of polio specialists. They argue that the 
understanding of the underlying genomic structures has 
advanced so far that there is very little study, and few 
techniques or therapies, that are truly specific to the heart. 
Cardiac surgery has all but disappeared. Almost all heart 
therapy is now preventive and is carried out either through 
plaarmaceuticals (now considered old fashioned) or through 
nnformation exchange to the universal bio-assemblers. By 
m~w, in the mid-twenty-first century, there are still many 
t?.qges of medical specialties; but the trend of the era is to 
build specialties not around organs or systems but around 
ways of looking at the overall system, such as genomics, 
proteomics, medical nanomics, systems biology, and bioin- 
tormatics. 
But the voices of the mainstream argue that the College 
still has a mission that is central to the practice of medicine. 
The heart, with its attendant systems, remains the central 
driver of the body, with their own special problems. In fact, 
during the half-century from 1999 to 2049, the ACC has 
rapidly evolved, linking these new sources of knowledge 
directly to the actual field practice of cardiovascular medi- 
cine. It is this rapid, practical response that has succeeded in
taming what once was the greatest killer of all. 
REALITY CHECK 
All discussion of the future is, of course, some species of 
,fl~eculation. No one can truly know the future. These 
speculations, however, are based on current research efforts 
and the possibilities they bring to light extrapolated into the 
future. 
Most of the near-term possibilities are based on the 
reasonable supposition that discoveries and techniques that 
are new today will be refined during the next 10 years. They 
will come into common use to the extent hat they are found 
t~ be useful, safe, and affordable. Most of the possibilities 
fiom 10 to 25 years in the future are extrapolations from 
current research and are necessarily more speculative. 
Beyond 25 years from now, we are making reasonable 
guesses. In most cases, results that depend on engineering 
(e.g., robotics, imaging) come more quickly and more 
certainly than results that directly involve biology (e.g., 
nco-organs) or results that depend on popular awareness 
(e.g., switching to cholesterol-controlling margarines). Bi- 
ology and sociology are far more complex than engineering. 
In all cases, of course, the speculations spring from where 
we are today. 
Genomics. A rough draft of the complete human genome 
should be ready by mid-2000, and a final draft within two 
years (31). Human Genome Sciences, Inc., claims to have 
already mapped nearly all of the genes that actually express 
in the human body (32). A group of 11 major pharmaceu- 
tical companies has founded the SNP Consortium with a 
$45 million budget and the goal of mapping an estimated 
300,000 SNPs. 
The task of identifying all of the proteins in the human 
body is also proceeding apace, compficated by the fact that 
estimates of their numbers range from roughly 100,000 (the 
number of human genes) to 100 million. Much of the 
enormous task of finding the patterns of genes, proteins, 
and SNPs that signal disease or genetic predisposition to 
disease remains to be done--and the task is highly complex. 
However, it is not necessary to wait for all of the genomic 
information to be in place before it becomes clinically useful. 
Already, at the beginning of 2000, one biotechnology firm 
began offering a home DNA kit that would allow consumers 
to test their blood for SNPs that herald adverse drug 
reactions (33). According to the Biotechnology Industry 
Organization, by mid-1999 more than 80 pharmaceuticals 
derived from this information had already been approved by 
the Food and Drug Administration (FDA), more than 350 
were in various stages of FDA testing, and more than 
10,000 compounds have been identified as targets for testing 
as possible drugs over the next five years (34). 
The examples ofgenomic drugs mentioned previously are 
in various stages of development: 
• Cholesterol-controlling statins are available but underuti- 
lized (35-38); 
• Several types ofangiogenesis VEGF are in human clinical 
trials; early results have been mixed, but the idea still 
seems ound (39,40); 
• Endostatin has recently been shown to be effective in 
forestalling the growth of arterial plaque (41,42); 
• Myogenesis drugs, antiglycosylation therapies, and 
genomic therapies to repair damage after myocardial 
infarction are still in early research stages (43-46); 
• An HDL-raising vaccine has been successful in animal 
trials (47,48); 
• A nicotine vaccine has been successfully tested in labora- 
tory rats, with human trials planned within two years (49); 
• Whether prophylactic antibiotics might help prevent 
cardiovascular disease is under active investigation 
(50,51). 
Surgery. Stents are in common use today. Interventionist 
and minimally invasive techniques are becoming more 
common (52). 
Beating-heart surgery was introduced in 1998 (53-56). 
Robotic heart surgery, pioneered by U.S. firms, entered the 
commercial market in Europe in 1998, and human clinical 
trials were launched in the U.S. in 1999. Early experience 
has proven that robots, with their more-than-human dex- 
terity, stability, and precision, can execute through mini- 
really invasive ports some operations for which human 
surgeons would have to open the chest (e.g., Attial-Septal 
Defect [ASD] closure) (57,58). It is not yet clear whether 
robotic surgery will ever become faster, more cost effective, 
or better for the patient han traditional surgery. 
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The single largest question about the future of cardiac 
surgery is how soon pharmaceutical dvances will actually 
cause a drop in the volume of procedures. Clearly, if even 
some of the current genomic lines of research produce useful 
results, then those pharmaceuticals will obviate the need for 
many of today's surgical and interventionist procedures. 
Successful VEGF drugs in particular could replace coronary 
artery bypass grafts (CABGs), the single most common 
major operation in the nation. The population is aging, yet 
the bulk of the baby boom generation will not reach the 
prime age for heart disease until after the year 2015. This 
question is of major importance for planners designing new 
surgical units and for medical schools educating cardiac 
surgeons. This area is a prime candidate for computer 
modeling that would test the sensitivity of various assump- 
tions. 
Imaging. Experimental techniques can combine data from 
different sources to produce three-dimensional, scalable 
images from any point of view with any level of transparency 
for different ypes of tissue (59-61). The extrapolation of 
these images into real-time, three-dimensional, noninter- 
ventionist "fly-throughs" of the human body largely depends 
on further large advances in computing capacity. Although 
Moore's Law (which postulates an 18-month doubling 
period in computer power) is experiencing some fundamen- 
tal physical problems, a range of investigations, ranging 
from single-molecule ogic gates to quantum computing, 
allows us to imagine that Moore's Law will continue to 
operate, and computing power will continue to increase at a 
rapid pace (62-66). 
Replacement hearts. Electromechanical replacement hearts 
are ready to enter human clinical trials in this calendar year 
(67). The idea that such hearts may someday be able to beat 
without an outside battery is purely speculative. Clearly, the 
human body has such power available, as it powers the native 
heart, but so far no artificial muscle that derives energy from 
native metabolic processes has been developed. 
Swine hearts are similarly ready for human trials, accord- 
ing to the chief proponent of the technique, Dr. Jeffrey Platt 
of the Xenotransplant Institute at the Mayo Clinic, in 
Rochester, Minnesota (68). The concern that swine hearts 
might introduce porcine retroviruses into humans has 
proven ill-founded (69). 
Research into building neo-organs has shown that heart 
muscle cells can be cultured outside of the body, grown on 
a matrix into a thin, continuous heet, and made to beat as 
a unit (70). Other researchers have constructed arteries of 
bovine and porcine collagen coated with heparin (71). How 
long these experiments will take to produce flail lab-grown 
hearts is impossible to tell, but the possibility seems on the 
one hand to be quite real and on the other hand to be at least 
a generation in the future. 
Heart replacement may well become the dominant form of 
heart surgery, but looking ahead from 2000, it is not dear what 
the specific replacement will be---a mechanical heart, a swine 
heart xenograft, or a heart grown from the patient's own 
fibroblasts. A generation ahead, these operations may ulti- 
matdy be superceded by directly inducing fibroblasts to grow 
muscle, valve tissue, or arteries in situ to replace damaged 
tissue. 
Nanotech. Nanotechnology is still in its infancy--part 
theory, part basic design, and part experiment. Theoreti- 
clans have produced plausible designs of gears, pumps, and 
other basic mechanical structures built from altered hydro- 
carbon molecules. Experimenters have built molecular-scale 
propellers and rachets. At least one experimenter daims to 
have built basic shapes (e.g., cubes, octohedrons) as well as 
a crude logic gate by altering DNA molecules (72). Al- 
though the field seems promising, no one has yet built a 
working nanomachine of any kind. We are at least a 
generation away from useful nanoproducts. 
Patient data. A number of firms have pioneered the use of 
the Internet, in combination with blood pressure cuffs and 
other devices, to maintain constant contact between chronic 
heart failure patients and their health providers. Initial tests 
show significant drops in emergency room visits, hospital- 
izations, and cost as well as significant increases in func- 
tional ability (73-76). 
Smart cards, wallet-size CD-ROM cards, and Web sites 
that store patient medical records are already a reaht3'. 
Unfortunately, industry-wide technical standards for elec- 
tronic medical records have not yet been adopted, and a 
majority of health care systems till use paper records. The 
blocks to changing these practices are not technical but 
political, cultural, and economic. 
Standardization of diagnoses and clinical practice. The 
ACC's NCDR TM is one of the College's most important 
recent initiatives. Together with the ACC/American Heart 
Association Task Force on Practice Guidelines and the 
ACC expert consensus documents, the NCDR TM is in- 
tended to become a major force to spread best-practice 
knowledge throughout the specialty. 
"Just-in-time" knowledge. The pieces of a "just-in-time" 
knowledge system already exist. These include rapidly grow- 
ing databases of diagnostic and practice guidelines; "diag- 
nostic assistance" software; experiments with software that 
can recognize patterns in diagnosis, treatment, or pharma- 
ceuticals and offer new knowledge; Internet-ready personal 
digital assistants (PDAs) designed for medical use; and the 
World Wide Web to connect ogether the PDAs and the 
databases (77-82). Developing these pieces into a widely 
accepted, seamless ystem that would be a major enhance- 
ment of clinical practice is no longer a technical problem but 
an economic and cultural one. 
Life extension. Will all of these medical and technical 
, • 
breakthroughs actually extend people s lives. The answer is 
far from obvious, because it is a general-systems question, 
and our knowledge is largely about subsystems. Even curing 
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heart disease ntirely would only add a few years to the lives 
of bodies that are prey to many other diseases as well as to 
the multiple systemic degradations and failures that are part 
of the aging process. Yet the kind of deep understanding of 
human biochemistry that would lead to a complete cure of 
heart disease could not exist in a vacuum: such deep under- 
sumding would undoubtedly ead to cures, preventatives, or
powerful therapies for many other diseases and conditions. 
Furthermore, some studies, such as those on telomerase and 
glycosylation, seem to offer insight into the aging process itself. 
It is on this general-systems question that our conclusions 
,ire dearly the most speculative. Yet, we believe that it is quite 
possible that the next 50 years will see the introduction of 
therapies that will allow people to five significantly onger lives. 
SUMMARY 
The fiftieth anniversary of the ACC and the end of the 
twentieth century are arbitrary points in time, yet they seem 
to coincide with a true watershed. The last 50 years have 
brought a rush of new techniques and understandings that 
have, for the first time, given cardiovascular specialists real 
tools to prevent and fight cardiovascular disease. Only now, 
for the first time, has science begun to understand exactly 
what happens when plaque forms in an artery, when heart 
muscle fibers cross-link and weaken, when an atrial chamber 
fibrillates, and when heart muscle cells die en masse after a 
heart attack. We are beginning to track down the actual 
chemical, mechanical, and electrical pathways by which the 
heart is damaged or dies. When we can interfere with those 
pathways and stop the chain of events, we will have defeated 
heart disease. 
Imagination is rapid, but progress is often both uncertain 
and slow because of the many constraints of cost, regulation, 
and time needed to test and evaluate new developments. Yet 
we can now foresee a future in which medical science 
might actually defeat cardiovascular disease the way it has 
defeated polio, smallpox, and other serious scourges of 
the past. 
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Technology is ineluctably human. It could be said that our 
ability to produce technology is what defines us as humans. 
It is who we are. 
Technology is driven by our desires. So, it is not surpris- 
ing that every new development prompts debates about 
ethics, morality, and philosophy. These debates can be 
boiled down to the questions, '%Vho are we, as humans?" 
arid WVhat do we really want?" 
These questions became specially vivid during the cri- 
tiques and discussions around early versions of this report. 
For instance, some new developments raise the possibility of 
extending the human life span beyond its current limits. 
That possibility is not at all a consensus goal among physicians 
or cardiovascular specialists. Some consider it morally suspect. 
The moral, ethical, legal, and social issues raised by these 
new technologies include the following: 
GENOMICS 
Privacy. I f  it becomes possible by mapping the SNPs in 
your genome to determine not only which diseases and 
syndromes you have now but also which ones you are likely 
to have in the future, to whom should this information be 
made available? Your insurors? Your employer? Your pro- 
spective mployers? Your school? Your spouse? Your dating 
partners? Your friends and neighbors? Government agen- 
des? 
Wherever we draw the bright line of privacy, how should 
we enforce it? What should we do about he black market in 
genomic information that will inevitably develop? 
Do we have a right to not know our own future? If  you 
could know your own health future decades in advance, 
would you want to? Will we be able to refuse the knowledge, 
or will it be forced on us? 
Cost. Already, one of the greatest problems that physicians 
report in getting patients to comply with their drug regi- 
mens is that the patients imply cannot afford the drugs. 
Many older people, especially those who are living on fixed 
incomes and facing multiple health problems, have to 
choose between eating and taking a full course of their heart 
medicine. The new drugs derived from genomic informa- 
tion may greatly exacerbate this problem. Some will be 
inexpensive. Many will be expensive but cheaper than the 
